FierceBiotech, Mass High Tech, BIO's SmartBrief and the BBJ cover Konstantin Linnik’s advisory on FDA’s rules on biosimilars. Konstantin, a partner in the firm's Life Sciences practice group and a former senior corporate counsel at Pfizer, discusses the FDA’s new rules on biosimilars, which are prompting companies to take a close second look at what they keep secret and how they pursue an effective IP strategy for their products. "Companies are starting to think about what to patent and what to keep as a trade secret, and how to protect a trade secret," Konstantin Linnik tells Mass High Tech.
Click here for the FierceBiotech article.
Click here for the Mass High Tech article.